Cheaper pain relief after breast surgery? new trial puts generic to the test
NCT ID NCT07154446
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study compares a generic painkiller (Parestat) to the original brand-name drug (Dynastat) for pain after breast surgery. Sixty adults having a breast biopsy will be randomly assigned to receive one of the two drugs during surgery. Researchers will measure pain levels and side effects over 24 hours to see if the generic works just as well.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- parecoxib (a painkiller given intravenously during surgery)
- What this could lead to
- If it works, this could show that the cheaper generic version is just as good as the original for managing post-surgery pain.
- What could go wrong
- This is a small, early-phase trial with only 60 people, so results may not apply to everyone. There is also a chance the generic is slightly less effective.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
About 60 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Oct 2025
An estimate. Start dates often move.
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 65 years
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Patients aged 18 years or older. Patients scheduled for elective excision biopsy of the breast. Patients with an American Society of Anesthesiologists (ASA) physical status classification of I or II. Patients who can understand and provide written informed consent. Exclusion Criteria: Patients with a known allergy or contraindication to parecoxib or any of its excipients. Patients with a history of severe gastrointestinal bleeding, ulceration, or perforation. Patients with a history of significant cardiovascular disease (e.g., unstable angina, recent myocardial infarction, stroke). Patients with uncontrolled hypertension. Patients with severe renal impairment (creatinine clearance \< 30 mL/min). Patients with severe hepatic impairment (Child-Pugh Class C). Patients who are pregnant or breastfeeding. Patients taking medications that are contraindicated with parecoxib (refer to drug interaction section). Patients with a history of bronchospasm, acute rhinitis, nasal polyps, angioedema, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Breast exicision biopsy are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.